tetano
Editor, Senior Moderator
Immun Inflamm Dis
. 2021 Aug 18.
doi: 10.1002/iid3.471. Online ahead of print.
Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
Zhengchuan Zhu[SUP] 1 [/SUP], Miaoran Wang[SUP] 2 [/SUP], Wei Lin[SUP] 3 4 [/SUP], Qiaoyan Cai[SUP] 3 4 5 [/SUP], Ling Zhang[SUP] 3 4 5 [/SUP], Daxin Chen[SUP] 3 4 5 [/SUP], Fei Liu[SUP] 3 4 [/SUP], Xiaoman Xiong[SUP] 3 4 [/SUP], Jianfeng Chu[SUP] 3 4 5 [/SUP], Jun Peng[SUP] 3 4 5 [/SUP], Keji Chen[SUP] 1 2 6 [/SUP]
Affiliations
Abstract
Aims: To explore the correlation between cardiac-related comorbidities, cardiac biomarkers, acute myocardial injury, and severity level, outcomes in COVID-19 patients.
Method: Pubmed, Web of Science, Embase, CNKI, VIP, Wanfang, Cochrane Library databases, medRxiv, and Sinomed were reviewed systemically. Various types of clinical research reporting cardiac-related comorbidities, cardiac biomarkers including lactate dehydrogenase (LDH), troponin I (TnI), high sensitivity troponin I (hs-TnI), creatine kinase (CK), creatine kinase-MB (CK-MB), myoglobin (Myo), N-terminal pro-b-type natriuretic peptide (NT-proBNP) and acute cardiac injury grouped by severity of COVID-19 were included. Outcome measures were events and total sample size for comorbidities, acute cardiac injury, and laboratory parameters of these biomarkers. The study was performed with Stata version 15.1.
Results: Seventy studies, with a total of 15,354 cases were identified. The results showed that COVID-19's severity was related to cardiovascular disease. Similar odds ratios (ORs) were achieved in hypertension except for severe versus critical group (OR = 1.406; 95% CI, 0.942-2.097; p = .095). The relative risk (RR) of acute cardiac injury is 7.01 (95% CI, 5.64-8.71) in non-survivor cases. When compared with the different severity of cardiac biomarkers, the pool OR of CK, CK-MB, TnI, Myo and LDH were 2.683 (95% CI, 0.83-8.671; p = .106; I[SUP]2[/SUP] = 0%), 2.263 (95% CI, 0.939-5.457; p = .069), 1.242 (95% CI, 0.628-2.457; p = .534), 1.756 (95% CI, 0.608-5.071; p = .298; I[SUP]2[/SUP] = 42.3%), 1.387 (95% CI, 0.707-2.721; p = .341; I[SUP]2[/SUP] = 0%) in the critical versus severe group, whose trends were not similar to other groups. The standard mean differences (SMD) of CK and TnI in the critical versus severe group were 0.09 (95% CI, -0.33 to 0.50; p = .685; I[SUP]2[/SUP] = 65.2%), 0.478 (95% CI, -0.183 to 1.138; p = .156; I[SUP]2[/SUP] = 76.7%), which means no difference was observed in the serum level of these indicators.
Conclusion: Most of the findings clearly indicate that hypertension, cardiovascular disease, acute cardiac injury, and related laboratory indicators are associated with the severity of COVID-19. What is now needed are cross-national prospectively designed observational or clinical trials that will help improve the certainty of the available evidence and treatment decisions for patients.
Keywords: COVID-19; SARS-CoV-2; acute myocardial injury; cardiac biomarkers; comorbidities; meta-analysis.
. 2021 Aug 18.
doi: 10.1002/iid3.471. Online ahead of print.
Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
Zhengchuan Zhu[SUP] 1 [/SUP], Miaoran Wang[SUP] 2 [/SUP], Wei Lin[SUP] 3 4 [/SUP], Qiaoyan Cai[SUP] 3 4 5 [/SUP], Ling Zhang[SUP] 3 4 5 [/SUP], Daxin Chen[SUP] 3 4 5 [/SUP], Fei Liu[SUP] 3 4 [/SUP], Xiaoman Xiong[SUP] 3 4 [/SUP], Jianfeng Chu[SUP] 3 4 5 [/SUP], Jun Peng[SUP] 3 4 5 [/SUP], Keji Chen[SUP] 1 2 6 [/SUP]
Affiliations
- PMID: 34405950
- DOI: 10.1002/iid3.471
Abstract
Aims: To explore the correlation between cardiac-related comorbidities, cardiac biomarkers, acute myocardial injury, and severity level, outcomes in COVID-19 patients.
Method: Pubmed, Web of Science, Embase, CNKI, VIP, Wanfang, Cochrane Library databases, medRxiv, and Sinomed were reviewed systemically. Various types of clinical research reporting cardiac-related comorbidities, cardiac biomarkers including lactate dehydrogenase (LDH), troponin I (TnI), high sensitivity troponin I (hs-TnI), creatine kinase (CK), creatine kinase-MB (CK-MB), myoglobin (Myo), N-terminal pro-b-type natriuretic peptide (NT-proBNP) and acute cardiac injury grouped by severity of COVID-19 were included. Outcome measures were events and total sample size for comorbidities, acute cardiac injury, and laboratory parameters of these biomarkers. The study was performed with Stata version 15.1.
Results: Seventy studies, with a total of 15,354 cases were identified. The results showed that COVID-19's severity was related to cardiovascular disease. Similar odds ratios (ORs) were achieved in hypertension except for severe versus critical group (OR = 1.406; 95% CI, 0.942-2.097; p = .095). The relative risk (RR) of acute cardiac injury is 7.01 (95% CI, 5.64-8.71) in non-survivor cases. When compared with the different severity of cardiac biomarkers, the pool OR of CK, CK-MB, TnI, Myo and LDH were 2.683 (95% CI, 0.83-8.671; p = .106; I[SUP]2[/SUP] = 0%), 2.263 (95% CI, 0.939-5.457; p = .069), 1.242 (95% CI, 0.628-2.457; p = .534), 1.756 (95% CI, 0.608-5.071; p = .298; I[SUP]2[/SUP] = 42.3%), 1.387 (95% CI, 0.707-2.721; p = .341; I[SUP]2[/SUP] = 0%) in the critical versus severe group, whose trends were not similar to other groups. The standard mean differences (SMD) of CK and TnI in the critical versus severe group were 0.09 (95% CI, -0.33 to 0.50; p = .685; I[SUP]2[/SUP] = 65.2%), 0.478 (95% CI, -0.183 to 1.138; p = .156; I[SUP]2[/SUP] = 76.7%), which means no difference was observed in the serum level of these indicators.
Conclusion: Most of the findings clearly indicate that hypertension, cardiovascular disease, acute cardiac injury, and related laboratory indicators are associated with the severity of COVID-19. What is now needed are cross-national prospectively designed observational or clinical trials that will help improve the certainty of the available evidence and treatment decisions for patients.
Keywords: COVID-19; SARS-CoV-2; acute myocardial injury; cardiac biomarkers; comorbidities; meta-analysis.